Financial Post
🏢 Postmedia
📍 ON
May 19, 2026
· 2 min read
AI Analyzed
○ Unverifiable
View full audit trail →
Boaz Weinstein’s Hedge Fund Takes Aim at Impax’s ‘Terrible’ Run
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.257 · RIGHT
Ensemble
0.129 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.026
5,041 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Boaz Weinstein's hedge fund Saba Capital Management is taking a significant position against Impax Laboratories Inc., as the company struggles with an "epic failure" of its Alzheimer's drug candidate and faces numerous challenges.
In a filing to the Securities and Exchange Commission (SEC), Saba disclosed that it now owns 5.18% of Impax’s shares, up from just over 3% in December. The fund's stake is worth approximately $74 million, based on Impax's stock price at the end of last year.
Saba isn't alone in its skepticism about Impax. Analysts have been warning for months that the company faces…
Read full article at Financial Post ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1 + full
Jun 3, 2026